secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2026-08-19T21:07:17+00:00
Accession:  0001193125-26-357120
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences grants CEO and CFO restricted stock with market-cap vesting
--------------------------------------------------------------------------------

- CEO James Rolke granted 208,076 restricted shares; CFO Chester Zygmont granted 208,073 shares, effective Aug 17, 2026.
- Awards vest in four 25% tranches upon 20-day market caps of $30M, $60M, $90M, $120M, or by 2nd/4th anniversaries.
- Full vesting on change in control; accelerated on death, termination without cause, or for good reason.
- Unvested shares forfeited on termination for cause, disability, or retirement; dividends held with same restrictions.
- Grants made under Amended and Restated 2021 Equity Incentive Plan; form of award agreement filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/0001193125-26-357120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-357120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer